DDInter478 DDInter1376
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Daratumumab may lead to a major life threatening interaction when taken with Cladribine
Daratumumab may lead to a major life threatening interaction when taken with Rotavirus vaccine